Zevra Therapeutics, a company focused on ultra-rare diseases, presented its growth strategy at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026. The company, which has a portfolio of treatments for rare diseases, aims to expand its commercial presence and global reach.
Zevra Therapeutics has approximately $260 million in financial resources available for strategic use. The company has more cash than debt and used proceeds from non-core asset monetization to repay debt with double-digit interest rates. The company's stock price is trading around $12.01, up 34% year-to-date and 67% over the past year, but 22% below its 52-week high of $15.04.
The company's flagship product, MIPLYFFA (arimoclomol), is approved for Niemann-Pick disease type C (NPC) and has seen significant growth. By the end of Q2, Zevra had 184 prescription enrollment forms in the U.S., up from an initial estimate of 300 to 350 patients. The company has also expanded its reach in Europe, with an estimated diagnosed patient population of about 1,100. The company's total addressable market (TAM) estimate for NPC has been revised upwards to 350 to 900 patients, reflecting a more accurate understanding of the disease's prevalence.
Zevra Therapeutics is also advancing celiprolol, a treatment for vascular Ehlers-Danlos syndrome (vEDS), through its phase III program. As of the end of Q2, 66 out of 150 planned patients had been enrolled, with only 3 events recorded so far. The company plans to reengage with the FDA in the second half of the year.
Neil McFarlane, Chief Executive Officer of Zevra Therapeutics, emphasized the company's focus on commercializing products for ultra-rare diseases. He noted that the company is expanding MIPLYFFA in Europe and has a phase III program ongoing with celiprolol. McFarlane also highlighted the company's strategy of piloting activities and investments, doubling down on successful initiatives and killing those that do not work.
Justin Renz, Chief Financial Officer of Zevra Therapeutics, provided an update on the company's financial position. He stated that Zevra has about $260 million in cash and other resources available for strategic use, is generating positive cash flow, and maintains a lean, rare-disease-focused operational profile.
